Molecular profile can influence the PFS in radioiodine-refractory thyroid cancer patients treated with lenvatinib

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Molecular profiling of advanced thyroid cancer: characterizing tumors for targeted treatment2024
2. 2Single cell analysis of a thyroid cancer cell line resistant to lenvatinib2024
3. 3TP53 mutations associate with poor response to lenvatinib treatment for advanced thyroid cancer2024
4. 4Neoadjuvant lenvatinib in invasive differentiated thyroid cancer2024
5. 5Impact of genomic biomarkers on treatment decisions and clinical outcomes in patients with radioiodine-refractory thyroid cancer and treatment with multi-tyrosine kinase inhibitors - a multi-center registry analysis2024